FeesSafety
Pluang+

Medtronic reports Q3 earnings post-MiniMed spin-off with expected revenue growth but margin pressures.

Company Fundamentals
21 Nov 2026, 21:07 WIB
The Motley Fool
View Source
Neutral
Medtronic reports Q3 earnings post-MiniMed spin-off with expected revenue growth but margin pressures.

Medtronic will release its Q3 fiscal 2027 earnings on Nov. 24, marking its first report after spinning off its diabetes unit, MiniMed, in October. The company expects a 6% revenue increase year-over-year but anticipates a 2% dip in adjusted earnings per share due to reinvestments and margin pressures from new manufacturing costs and acquisitions. Medtronic's revenue grew strongly in fiscal 2026, and it forecasts further growth in fiscal 2027, driven by its cardiovascular and neuroscience businesses. Investors are advised to watch how the company manages margin pressures before considering it a stable dividend stock.

As Medtronic prepares to report its first earnings since spinning off MiniMed, the stocks reflect cautious sentiment. On Pluang, Medtronic (MDT) trades at USD 99.94, down 0.67% as of Nov 22, 2026 02:01 WIB, with a dividend yield of 2.88%. Meanwhile, MiniMed (MMED) is priced at USD 16.01, down 1.54% at the same time, showing shorter typical hold times compared to Medtronic.

More News (MDT)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App